Theravance Biopharma (TBPH) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/3/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's revenue misses estimates as AI chip race heats up, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Alphabet plans $80 billion equity raise to fund AI infrastructure expansion, Berkshire Hathaway to invest $10 billion
- Alphabet plans $80 billion raise for AI, backed by Buffett’s Berkshire
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Theravance Biopharma, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update
November 7, 2017 4:02 PM ESTDUBLIN, Nov. 7, 2017 /PRNewswire/ --Â Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the third quarter ended September 30, 2017. Revenue for the third quarter of 2017 was $4.3 million. The third quarter operating loss was $57.0 million, or $46.3 million excluding non-cash share-based compensation expense of $10.7 million. Cash, cash equivalents, and marketable securities totaled $434.4 million as of September 30, 2017.
... More